logo_image
Headline: Strategic Advisory for Leading Therapeutics Innovation Inc. (SALTI) Launches as New Management Consulting Firm
Location: US
Post Date: May 1, 2024 10:15 AM
TAG ID: awire157848
DocID: 858453
Word Count: approx. 470 words
 
 
Full story:


The new firm promises to bring a new model for a consulting partner in the life sciences industry.

NEW YORK, NY / ACCESSWIRE / May 1, 2024 / Strategic Advisory for Leading Therapeutics Innovation Inc. ( SALTI ) is proud to announce its official launch, poised to set a new standard in life sciences consulting. Sherif Salti Speaking During Launch Announcement Founder and Global Managing Partner, Sherif Salti, promises a new model for a consulting partner with his new firm.

Founded by Sherif Salti, a distinguished leader in digital transformation within the life sciences sector, SALTI is uniquely positioned to offer a differentiated partnership. Drawing on his extensive track record of successful transformations across the industry, the firm is designed to capitalize on emerging opportunities and drive significant advancements in life sciences commercialization. Expanding on the vision of its founder to "Advance Medicine, Transform Lives," SALTI integrates a powerhouse team with expertise in launch excellence, digital transformation, scientific and medical advisory, advanced analytics, among others.

Ray Gomez, reflecting on his partnership with Sherif Salti over the years that shaped transformative strategies globally during his past collaborations as Vice President of Worldwide Omnichannel Capabilities at Bristol Myers Squibb, lauded his contributions: "Sherif Salti is an exceptional leader whose profound expertise and unwavering dedication have been pivotal in our transformation initiatives. His strategic acumen and meticulous attention to detail have been crucial in navigating complex challenges and delivering superior outcomes."

In an industry propelled by rapid innovation and intricate challenges, the strategic importance of specialty markets cannot be overstated. Oncology, as the leading area of medicine costs globally with a projected spend of $377 billion by 2027, highlights the critical need for specialized expertise within life sciences organizations. Parallel to this, the rise of emerging biopharmaceutical companies marks a crucial industry trend. These agile and innovative entities often find themselves hindered by the bureaucratic inertia typical of larger, traditional options for strategic advisory partners. Such companies, vital for driving sector-wide innovation, require partners who mirror their agility and can adapt swiftly to changing market dynamics.

SALTI, with its focused, agile teams, is uniquely equipped to meet these needs. The new firm's approach delivers clear, strategic insights without the burdensome overhead of conventional models, fostering an environment where strategic planning seamlessly transitions into impactful execution.

Sherif Salti elaborates on the firm's operational ethos: "Our aim is to enhance our clients' ability to innovate autonomously. We provide the roadmap and tools, but our goal is to empower clients to lead their own advancements effectively. To that end, a forthcoming roadmap from SALTI includes the introduction of strategic capability 'accelerators'-tools and frameworks designed to significantly enhance the efficiency and effectiveness of life sciences capabilities, particularly for new product launches."

Contact Information

Media Relations [email protected] 2122081410

Related Video

https://www.youtube.com/watch?v=JYSe8x4I0JU

SOURCE: Strategic Advisory for Leading Therapeutics Innovation Inc.

View the original press release on newswire.com.

 
Please login to download this Story